Life at Lilly

It's tough times at Eli Lilly with patents ending, failed drugs, among other problems, reports the New York Times. But CEO John Lechleiter says that Lilly doesn't need to turn to mergers or acquisitions to jump-start the company; he says they can rely on in-house research and cost-cutting. "At a time when others say Lilly has to do a deal or Lilly has to go outside itself to solve its problems, we're resolutely focused on what we have to do inside the company," Lechleiter says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.